Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Equity Average: 2015-2025

Historic Equity Average for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $113.6 million.

  • CytomX Therapeutics' Equity Average rose 515.70% to $113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year increase of 515.70%. This contributed to the annual value of -$24.0 million for FY2024, which is 64.04% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Equity Average stood at $113.6 million, which was up 56.80% from $72.5 million recorded in Q2 2025.
  • CytomX Therapeutics' Equity Average's 5-year high stood at $113.6 million during Q3 2025, with a 5-year trough of -$86.2 million in Q1 2023.
  • Over the past 3 years, CytomX Therapeutics' median Equity Average value was -$31.5 million (recorded in 2024), while the average stood at -$18.3 million.
  • Per our database at Business Quant, CytomX Therapeutics' Equity Average plummeted by 654.80% in 2022 and then skyrocketed by 515.70% in 2025.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Equity Average stood at $15.0 million in 2021, then slumped by 654.80% to -$83.1 million in 2022, then skyrocketed by 40.66% to -$49.3 million in 2023, then skyrocketed by 75.77% to -$12.0 million in 2024, then surged by 515.70% to $113.6 million in 2025.
  • Its last three reported values are $113.6 million in Q3 2025, $72.5 million for Q2 2025, and $12.3 million during Q1 2025.